

# MARK3 [6His-tagged]

Kinase

**Alternate Names:** MAP/Microtubule Affinity-regulating Kinase 3; MARK3; Microtubule-associated Protein/Microtubule Affinity-regulating Kinase 3. CDC25C-associated Protein Kinase 1; CTAK1

**Cat. No.** 66-0004-050

**Lot. No.** 2135

**Quantity:** 50 µg

**Storage:** -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 1 of 2

## Background by Sir Phillip Cohen

Protein ubiquitylation and protein phosphorylation are the two major mechanisms that regulate the functions of proteins in eukaryotic cells. However, these different posttranslational modifications do not operate independently of one another, but are frequently interlinked to enable biological processes to be controlled in a more complex and sophisticated manner. Studying how protein phosphorylation events control the ubiquitin system and how ubiquitylation regulates protein phosphorylation has become a focal point of the study of cell regulation and human disease. Cloning of human Microtubule Affinity Regulating Kinase 3 (MARK3) was first described by Peng *et al.* (1998). MARK3 is a member of the subfamily of protein kinases that include the AMP-activated protein kinase (AMPK) and, like AMPK itself, is activated by the tumour suppressor kinase LKB1 (Lizcano *et al.*, 2004). The physiological roles of the MARK subfamily of protein kinases include the phosphorylation of microtubule associated proteins and the regulation of cell polarity. Members of the MARK sub-family also phosphorylate tau at sites that induce its dissociation from tubulin. Enhanced phosphorylation of these sites is an early hall mark of Alzheimer's disease and is followed by abnormal aggregation of tau to paired helical filaments that are found in people with Alzheimer's disease (Marx *et al.*, 2010). MARK3 con-

Continued on page 2

## Physical Characteristics

**Species:** human

**Source:** Sf21 insect cell-baculovirus expression

**Quantity:** 50 µg

**Concentration:** 1 mg/ml

**Formulation:** 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 150 mM NaCl, 270 mM sucrose, 0.03% Brij, 0.1% β-Mercaptoethanol, 1 mM Benzamidine, 0.2 mM PMSF

**Molecular Weight:** ~86.1 kDa


**Purity:** >70% by InstantBlue™ SDS-PAGE

**Stability/Storage:** 12 months at -70°C; aliquot as required

**Protein Sequence:** Please see page 2

## Quality Assurance

**Purity:**  
4-12% gradient SDS-PAGE  
InstantBlue™ staining  
Lane 1: MW markers  
Lane 2: 1 µg His-MARK3



**Protein Identification:**  
Confirmed by mass spectrometry.

**Activity Assay:**  
The specific activity of His-MARK3 was determined using the method described by Hastie *et al.* (2006) with the enzyme being assayed at several concentrations. His-MARK3 was incubated for 10 minutes at 30°C in kinase reaction buffer in the presence of CHKtide substrate (300 µM) and [ $\gamma$ -<sup>32</sup>P]ATP (100 µM). Duplicate reactions were stopped by spotting the assay mixture onto Whatman P81 paper – capturing the phosphorylated substrate. The radioactivity incorporated was measured on a scintillation counter and the enzyme's mean specific activity was calculated.

**His-MARK3 specific activity:**  
282.0 Units/mg (282.0 Units/ml)

1 Unit = 1 nmole of phosphate incorporated into the substrate in 1 minute

Substrate: CHKtide (KKKVSRSGLYRSPSPENLNRPR)



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

**International:** +1-617-245-0003  
**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233)  
**Email:** sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT

**International:** +44 (0) 1382 381147 (9AM-5PM UTC)  
**US/Canada:** +1-617-245-0020 (9AM-5PM UTC)  
**Email:** tech.support@ubiquigent.com

Email services@ubiquigent.com for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

**Limited Terms of Use:** For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

# MARK3 [6His-tagged]

Kinase

**Alternate Names:** MAP/Microtubule Affinity-regulating Kinase 3; MARK3; Microtubule-associated Protein/Microtubule Affinity-regulating Kinase 3. CDC25C-associated Protein Kinase 1; CTAK1

**Cat. No.** 66-0004-050

**Lot. No.** 2135

**Quantity:** 50 µg

**Storage:** -70°C

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS



CERTIFICATE OF ANALYSIS Page 2 of 2

## Background by Sir Phillip Cohen

Continued from page 1

tains a ubiquitin-like domain adjacent to the kinase catalytic domain and, similar to MARK4, undergoes Lys29/Lys33-linked polyubiquitylation that may inhibit its activity. It may also interact with the deubiquitylase USP9X (Al-Hakim *et al.*, 2008).

### References:

Al-Hakim AK, Zagorska A, Chapman L, Deak M, Peggie M, Alessi DR (2008) Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. *Biochem J* 411, 249-60.

Hastie CJ, McLauchlan HJ, Cohen P (2006) Assay of protein kinases using radiolabeled ATP: a protocol. *Nat Protoc* 1, 968-71.

Lizcano JM, Goransson O, *et al.* (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J* 23, 833-43.

Marx A, Nugoer C, Panneerselvam S, Mandelkow E (2010) Structure and function of polarity-inducing kinase family MARK/Par-1 within the branch of AMPK/Snf1-related kinases. *FASEB J* 24, 1637-48.

Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, 3rd, Wu Z, Stephenson MT, Piwnicka-Worms H (1998) C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. *Cell Growth Differ* 9, 197-208.

Background kindly written by:

**Sir Phillip Cohen FRS, FRSE**  
University of Dundee

Director of the Medical Research Council Protein Phosphorylation Unit (1990-2012)

Director of the Scottish Institute for Cell Signalling incorporating the Protein Ubiquitylation Unit (2008-2012)

Co-Director of the Division of Signal Transduction Therapy (1998-2012)

Deputy Director of the Division of Signal Transduction Therapy (from July 2012)

*Professor Cohen's research group is studying the interplay between protein phosphorylation and protein ubiquitylation in the regulation of innate immunity.*

## Physical Characteristics

Continued from page 1

### Protein Sequence:

**MSY YHHHHHDYD I P T T ENLYF Q G A M G S**  
G I Q R P T S T S S L V A A A S T R T P L P T V N E R D  
T E N H T S H G D G R Q E V T S R T S R S G A R C R N  
S I A S C A D E Q P H I G N Y R L L K T I G K G N  
F A K V K L A R H I L T G R E V A I K I I D K T Q L N P T  
S L Q K L F R E V R I M K I L N H P N I V K L F E V I  
E T E K T L Y L I M E Y A S G G E V F D Y L V A H G R M  
K E K E A R S K F R Q I V S A V Q Y C H Q K R I V H R D L  
K A E N L L L D A D M N I K I A D F G F S N E F T V G  
G K L D T F C G S P P Y A A P E L F Q G K K Y D G P E  
V D V W S L G V I L Y T L V S G S L P F D G Q N L K E L  
R E R V L R G K Y R I P F Y M S T D C E N L L K R F L V  
L N P I K R G T L E Q I M K D R W I N A G H E E  
D E L K P F V E P E L D I S D Q K R I D I M V G M  
G Y S Q E E I Q E S L S K M K Y D E I T A T Y L L L  
G R K S S E L D A S D S S S S N L S L A K V R P S S  
D L N N S T G Q S P H H K V Q R S V S S S Q K Q R R Y S D  
H A G P A I P S V V A Y P K R S Q T S T A D G D L K E D G  
I S S R K S S G S A V G G K G I A P A S P M L G  
N A S N P N K A D I P E R K K S S T V P S S N T A S  
G G M T R R N T Y V C S E R T T A D R H S V I Q N G  
K E N S T I P D Q R T P V A S T H S I S S A A T P  
D R I R F P R G T A S R S T F H G Q P R E R R T A T Y N  
G P P A S P S L S H E A T P L S Q T R S R G S T N L F  
S K L T S K L T R S R N V S A E Q K D E N K E A K  
P R S L R F T W S M K T T S S M D P G D M M R E I R K V  
L D A N N C D Y E Q R E R F L L F C V H G D G H A E N  
L V Q W E M E V C K L P R L S L N G V R F K R I S G T  
S I A F K N I A S K I A N E L K L

Tag (**bold text**): N-terminal His  
Protease cleavage site: TEV (**ENLYF**▼**QG**)  
MARK3 (regular text): Start **bold italics** (amino acid residues 2-729)  
Accession number: AAC15093.1



www.ubiquigent.com  
Dundee, Scotland, UK

### ORDERS / SALES SUPPORT

**International:** +1-617-245-0003  
**US Toll-Free:** 1-888-4E1E2E3 (1-888-431-3233)  
**Email:** sales.support@ubiquigent.com

### UK HQ and TECHNICAL SUPPORT

**International:** +44 (0) 1382 381147 (9AM-5PM UTC)  
**US/Canada:** +1-617-245-0020 (9AM-5PM UTC)  
**Email:** tech.support@ubiquigent.com

Email [services@ubiquigent.com](mailto:services@ubiquigent.com) for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2011. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

**Limited Terms of Use:** For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0